合成大麻素ADB-BUTINACA在人体尿液及体内外代谢模型中的代谢比较  

Metabolic Comparison of the Synthetic Cannabinoid ADB-BUTINACA in Human Urine and in vivo and in vitro Metabolic Models

作　　者：古锟山 王继芬[1] 张瑛 覃仕扬 张文芳 吴昊 占志胜 GU Kun-shan;WANG Ji-fen;ZHANG Ying;QIN Shi-yang;ZHANG Wen-fang;WU Hao;ZHAN Zhi-sheng(School of Investigation,People’s Public Security University of China,Beijing 100038,China;Key Laboratory of Forensic Toxicology,Ministry of Public Security,Forensic Science Service of Beijing Public Security Bureau,Beijing 100192,China;Key Laboratory of Evidence Science of Ministry of Educatior,China University of Political Science and Law,Beijing 100088,China;Dian Regional Forensic Science Institute,Hangzhou 310007,China;Department of Forensic Pathology,Shanxi Medical University,Taiyuan 030600,China)

机构地区：[1]中国人民公安大学侦查学院,北京100038 [2]北京市公安司法鉴定中心,法庭毒物分析公安部重点实验室,北京100192 [3]中国政法大学,证据科学教育部重点实验室,北京100088 [4]浙江迪安司法鉴定中心,浙江杭州310007 [5]山西医科大学法医学院,山西太原030600

出　　处：《质谱学报》2023年第3期424-435,I0005,共13页Journal of Chinese Mass Spectrometry Society

基　　金：中央高校基本科研业务费专项资金(2021JKF208);公安部科技强警专项毒物毒品快速筛查检测方法研究(2021JC32);证据科学教育部重点实验室(中国政法大学)开放基金资助课题(2019KFKT04)。

摘　　要：本研究采用液相色谱-高分辨质谱法分析人体尿液样本、斑马鱼体内代谢模型以及肝微粒体体外代谢模型中N-(1-氨甲酰基-2,2-二甲基丙基)-1-丁基吲唑-3-甲酰胺(ADB-BUTINACA)的代谢情况。结果表明,共检测到45个ADB-BUTINACA代谢物,包括37个Ⅰ相代谢物和8个Ⅱ相代谢物,涉及9种代谢途径,其中有7个Ⅰ相代谢物为首次报道。通过对比代谢模型和人体尿液样本中的代谢物发现,斑马鱼体内代谢模型产生的代谢物更接近人体尿液样本,但无论是体内还是体外代谢模型,其代谢物排名与人体尿液样本具有较大差异,仅凭体内外代谢模型得到的代谢物数据难以直接用于真实样本的分析。通过对人体尿液样本中代谢物峰面积排名分析,建议将ADB-BUTINACA原型、M36、M19以及M16作为ADB-BUTINACA的生物标志物。New psychoactive substances(NPSs) have presented health and social threats globally for more than a decade.As of November 2021,more than 1100 NPSs have been reported to the United Nations Office on Drugs and Crime Early Warning Advisory.Among these NPSs,synthetic cannabinoids are the second-largest group of substances that simulate the effects of tetrahydrocannabinol,accounting for 29% of NPS.Unlike marijuana,these synthetic cannabinoids are unpredictable and dangerous for users.The side effects include neurological,psychotic,gastrointestinal,renal,cardiovascular,and even lethal consequences.N-(1-carbamoyl-2,2-dimethylpropyl)-1-butylindazole-3-carboxamide(ADB-BUTINACA) is a potent agonist of CB1 receptor agonist.It is an emerging synthetic cannabinoid that was first identified in Europe in 2019 and entered Singapore's drug scene in January 2020.In 2021,it was one of the most common synthetic cannabinoid receptor agonists(SCRAs) seized by the Beijing Drug Control Agency.Due to the unavailable toxicological and metabolic data,there is a need to establish urinary metabolite biomarkers for detection of ADB-BUTINACA consumption and elucidate its biotransformation pathways for rationalizing its toxicological implications.In this study,the metabolisms of ADB-BUTINACA in authentic urine samples,zebrafish in vivo metabolism model and liver microsome in vitro metabolism model were analyzed by liquid chromatography-high resolution mass spectrometry.A total of 45 metabolites were tentatively identified in authentic urine samples,including 37 phase I metabolites and 8 phase II metabolites,seven of which were novel metabolites.There were 9 metabolic pathways,including amide hydrolysis(carboxamide),N-dealkylation,dehydrogenation,hydrolysis,ketone formation,hydroxylation,N-butanoic acid,dihydrodiol and glucuronidation.Hydroxylation and hydrolysis were the main metabolic pathways in authentic urine.Among these metabolites,the dihydrodiol metabolite was considered the main metabolite of ADB-BUTINACA,as it was the most abundant.By

关 键 词：N-(1-氨甲酰基-2 2-二甲基丙基)-1-丁基吲唑-3-甲酰胺(ADB-BUTINACA) 人体尿液 体内外代谢模型 代谢物 

分 类 号：O657.63[理学—分析化学]